Tela Bio Inc (TELA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tela Bio Inc (TELA) has a cash flow conversion efficiency ratio of 2.148x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.17 Million) by net assets ($-5.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tela Bio Inc (TELA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Tela Bio Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Tela Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tela Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tela Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kentucky First Federal Bancorp
NASDAQ:KFFB
|
0.018x |
|
Altustfi
WAR:ALI
|
0.007x |
|
PetMed Express Inc
NASDAQ:PETS
|
-0.281x |
|
Cuhadaroglu Metal Sanayi ve Pazarlama AS
IS:CUSAN
|
0.946x |
|
Heartbeam Inc
NASDAQ:BEAT
|
-1.116x |
|
DP Aircraft I Limited
LSE:DPA
|
0.082x |
|
VirTra Inc
NASDAQ:VTSI
|
-0.039x |
|
Ibase Gaming
TWO:6441
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Tela Bio Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Tela Bio Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see TELA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.31 Million | $-28.22 Million | -4.470x | -205.82% |
| 2024-12-31 | $28.46 Million | $-41.59 Million | -1.462x | +32.45% |
| 2023-12-31 | $18.88 Million | $-40.86 Million | -2.164x | +24.03% |
| 2022-12-31 | $14.30 Million | $-40.75 Million | -2.849x | -88.12% |
| 2021-12-31 | $20.10 Million | $-30.43 Million | -1.514x | -203.54% |
| 2020-12-31 | $49.03 Million | $-24.46 Million | -0.499x | +39.49% |
| 2019-12-31 | $30.96 Million | $-25.52 Million | -0.824x | -670.38% |
| 2018-12-31 | $-137.86 Million | $-19.92 Million | 0.145x | -4.49% |
| 2017-12-31 | $-108.17 Million | $-16.37 Million | 0.151x | -- |
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue… Read more